Attarbaschi T, Kasper S
Klinische Abteilung für Allgemeine Psychiatrie, Medizinische Universität Wien, Währinger Gürtel 18-20, 1090 Wien, Osterreich.
Nervenarzt. 2006 Nov;77(11):1310-4, 1317-8, 1320-2. doi: 10.1007/s00115-006-2096-9.
The diagnosis and treatment of bipolar mania are extremely challenging. Therapeutic intervention for mania has traditionally relied on the use of lithium or divalproex as a first-line treatment option. However, due to the limited therapeutic range of these agents, typical neuroleptics have often been used. Although these have demonstrated efficacy in mania, they are often associated with significant side effects, especially extrapyramidal symptoms. Thus, atypical antipsychotics are increasingly preferred in the treatment of bipolar mania. In this review, data from controlled studies for several of the atypical antipsychotics in the treatment of mania are surveyed and issues in the selection of an appropriate atypical agent are discussed.
双相躁狂症的诊断和治疗极具挑战性。传统上,针对躁狂症的治疗干预主要依赖使用锂盐或丙戊酸作为一线治疗选择。然而,由于这些药物的治疗范围有限,常使用典型抗精神病药物。尽管这些药物已证明对躁狂症有效,但它们往往伴有显著的副作用,尤其是锥体外系症状。因此,非典型抗精神病药物在双相躁狂症的治疗中越来越受到青睐。在本综述中,我们调查了几种非典型抗精神病药物治疗躁狂症的对照研究数据,并讨论了选择合适的非典型药物时存在的问题。